Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen, Inc.    AMGN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Amgen, Inc. : Amgen 1Q Profit Rises 5.2% On Broad Sales Growth

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/24/2012 | 10:40pm CET

Amgen Inc.'s (AMGN) first-quarter earnings rose 5.2% as the biopharmaceutical company reported sales growth across many of its products, helping results beat expectations.

The company has been trying to bolster its research-and-development pipeline and grow sales of its bone-building drugs to help offset declining sales of its key anti-anemia drugs, which have slumped in recent years due to safety concerns and intensifying competition. Amgen recently completed $1.16 billion acquisition of Micromet Inc. (MITI), a deal expected to strengthen its cancer-drug research pipeline.

Amgen reported a profit of $1.18 billion, or $1.48 a share, up from $1.13 billion, or $1.20 a share, a year earlier. Excluding acquisition and restructuring-related expenses and other items, earnings were up at $1.61 from $1.34. Revenue increased 9.2% to $4.05 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.45 on revenue of $3.93 billion.

Operating margin rose to 36.4% from 34.9%.

Combined sales of Neulasta and Neupogen, which are used to ward off infections undergoing cancer treatment, rose 9% to $1.34 billion.

The company has been counting on its new bone-building drugs, Xgeva and Prolia, to boost overall sales growth. Sales of Xgeva, a drug designed to prevent bone injuries in cancer patients, were up 14% to $153 million. Sales of Prolia, for osteoporosis in women, were up 9% to $153 million.

Shares of Amgen, which affirmed its 2012 guidance, were up 1% to $69.32 in recent after-hours trading.

-By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMGEN, INC.
03/21 AMGEN INC. : (AMGN) Sank To A 1-Month Low After Repatha Study
03/20 ESPERION THERAPEUTICS INC (NASDAQ : ESPR): Get It While It’s Cheap
03/19 AMGEN : Analyses Of PCSK9 Inhibitor Prescription Rejection Rates Demonstrate Sig..
03/18 AMGEN : Lowering LDL Levels With Repatha® (Evolocumab) Did Not Adversely Affect ..
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17 Amgen and AXT slump while Adobe and Tiffany advance
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More news
Sector news : Bio Therapeutic Drugs
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
03/14 AstraZeneca ovarian cancer drug slows disease markedly in study
03/09 Bull market turns 8 - historical facts and figures
03/08 Compare and contrast - Trump's tweets vs private comments to CEOs
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
03/21 ABBVIE : Good For Value, Good For Growth
03/21 UPCOMING EVENTS : Alder's Migraine Test, Paratek's Antibiotic
03/21 Amgen (AMGN) Presents At Oppenheimer 27th Annual Healthcare Conference
03/21 Sanofi, Regeneron sue Amgen over eczema drug
03/21 AMERICAN COLLEGE OF CARDIOLOGY : No Repatha Of Glory
Advertisement
Financials ($)
Sales 2017 23 041 M
EBIT 2017 11 723 M
Net income 2017 8 124 M
Finance 2017 1 921 M
Yield 2017 2,70%
P/E ratio 2017 15,26
P/E ratio 2018 14,77
EV / Sales 2017 5,27x
EV / Sales 2018 4,66x
Capitalization 123 319 M
More Financials
Chart AMGEN, INC.
Duration : Period :
Amgen, Inc. Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Full-screen chart
Technical analysis trends AMGEN, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 186 $
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline Chief Financial Officer & Executive Vice President
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
Frank J. Biondi Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN, INC.14.53%123 319
CELGENE CORPORATION6.58%95 978
GILEAD SCIENCES, INC.-5.28%88 658
REGENERON PHARMACEUTIC..0.56%39 159
ACTELION LTD24.49%29 874
VERTEX PHARMACEUTICALS..22.22%22 369
More Results